LUCD luciddx.com: Net earnings per share growth forecast for next year

Lucid Diagnostics - graphic logo of issuer LUCD

The innovative EsoGuard test provides high diagnostic reliability, replacing invasive endoscopy. Price stability confirms the earnings per share (EPS) forecast for the coming year, where the latest value is recorded as 31.50. The financial stability of Lucid Diagnostics Inc. (LUCD) relies on inelastic demand in gastroenterology and the implementation of AI modules to automate laboratory reports, which optimizes the company's operating expenses.

LUCD - Lucid Diagnostics, Inc. Earnings growth forecast for next year over the range 07/04/2022 - 11/12/2026

LUCD (luciddx.com): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart Lucid Diagnostics Inc|LUCD - Analyst Median Target
- company stock capitalization data:
Market Value Lucid Diagnostics|LUCD - Total Company Value
- company book value details:
Accounting Value per Share Lucid Diagnostics|LUCD - Book Capitalization|Market Capitalization to Book Value Ratio luciddx.com|LUCD - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Lucid Diagnostics Inc.|LUCD - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Lucid Diagnostics|LUCD - Company Aggregate Debt|Debt to Book Value Lucid Diagnostics|LUCD - Company Long-Term Loans and Borrowings|Company Short-Term Debts Lucid Diagnostics|Quick Ratio luciddx.com
- earnings and market ratios statistics:
LUCD - Net Financial Result|Projected Future Earnings Lucid Diagnostics Inc.|LUCD - P/E Multiple|Forward P/E Multiple Lucid Diagnostics Inc.|LUCD - Price to Net Income Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lucid Diagnostics|LUCD - Operating profit before amortization|Earnings per share for the last twelve months Lucid Diagnostics|LUCD - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months luciddx.com|LUCD - Expected net earnings per share growth this year|Expected earnings per share growth for next year Lucid Diagnostics Inc.
General company analysis:Lucid Diagnostics Inc
Finished products of luciddx.com

The integration of the EsoGuard system into oncology diagnostic standards makes the profit growth forecast for the coming year an indicator of the monetization of the technological advantage of Lucid Diagnostics Inc. (LUCD). This metric calculates the expected change in earnings per share, assessing the business's future ability to generate free cash flow. By analyzing the trend of the forward net income figure, an investor determines the scaling pace of the ecosystem. Positive dynamics confirm the capital's resilience to costs and the reliability of debt service.

Competitor analysis for Lucid Diagnostics Inc.

Net earnings per share growth forecast for next year Agilent Tech|Quest Corp (DGX) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Illumina, Inc. (ILMN)|Net earnings per share growth forecast for next year EXAS (exactsciences.com)|Revvity - Expected earnings per share growth for next year|Earnings growth forecast for next year Bio-Rad Laboratories, Inc. BIO|Anbio Tech - Earnings growth forecast for next year|Nordion (SHC) - Expected earnings per share growth for next year|QDEL: Earnings growth forecast for next year|OPK - Consensus forecast of earnings per share growth for next year|CDNA (CareDx, Inc.) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year MRVI (Maravai LifeSciences Holdings)|Expected earnings per share growth for next year FLGT (Fulgent Corp)|LAB (Standard BioTools Corp) - Expected earnings per share trend next year|Earnings growth forecast for next year CTKB (Cytek Biosciences, Inc.)|OSUR: Projected earnings per share growth rate for next year|Exagen Diagnostics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year MDxHealth S.A. MDXH|PRE: Earnings growth forecast for next year|Insight Molecular Diagnostics Inc (IMDX) - Earnings growth forecast for next year|TRIB (Trinity Biotech PLC) - Earnings growth forecast for next year|PRPH - Net earnings per one share growth forecast for next year|Net earnings per share growth forecast for next year Ainos (AIMD)|Co-Diagnostics Inc - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Heart Test Laboratories Inc. HSCS|Biomerica Inc (BMRA) - Expected net earnings per share growth next year|CDIO - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year onconetix.gcs-web.com ONCO|VRAX (Virax Biolabs) - Expected earnings per share growth for next year|BJDX: Projected earnings per share increase next year|AWH (Vermillion) - Earnings growth forecast for next year|Accelerate Diagnostics Inc (AXDX) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year CNTG|Expected earnings per share growth for next year enzo.com ENZ|Net earnings per share growth forecast for next year Fresh2 Group FRES|Consensus forecast of earnings per share growth for next year Genetic Technologies Ltd (GENE)|ME: Expected earnings per share growth for next year|Expected earnings per share trend next year PMD (Psychemedics Inc)